JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
There are no items in your shopping cart
Featured Products
Axon 1494
CAS [955365-80-7]
MF C27H32N8O2MW 500.60
A potent and selective Wee1 kinase inhibitor in vitro and in vivo. MK 1775 abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors.
KEYWORDS: MK 1775 | supplier | Wee1 inhibitor | AZD1775 | Adavosertib | supplier | MK1775 | AZD-1775 | AZD 1775 | CAS [955365-80-7] | CDK1 | Wee1 | Inhibitor | cyclin-dependent kinase 1 | CDC2 | DNA damage | checkpoint | G2-phase | apoptosis | p53-deficient | solid tumor
List of publications using MK 1775 (Axon 1494) purchased from Axon Medchem
2-Allyl-1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-2-yl]-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one
[955365-80-7]
The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.
Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!
Download the Axon Ligands™ catalogue 2021 Spring Edition
* Required Fields